Literature DB >> 10591267

National probability samples in studies of low-prevalence diseases. Part I: Perspectives and lessons from the HIV cost and services utilization study.

M F Shapiro1, M L Berk, S H Berry, C A Emmons, L A Athey, D C Hsia, A A Leibowitz, C A Maida, M Marcus, J F Perlman, C L Schur, M A Schuster, J W Senterfitt, S A Bozzette.   

Abstract

OBJECTIVE: To examine the trade-offs inherent in selecting a sample design for a national study of care for an uncommon disease, and the adaptations, opportunities and costs associated with the choice of national probability sampling in a study of HIV/AIDS.
SETTING: A consortium of public and private funders, research organizations, community advocates, and local providers assembled to design and execute the study.
DESIGN: Data collected by providers or collected for administrative purposes are limited by selectivity and concerns about validity. In studies based on convenience sampling, generalizability is uncertain. Multistage probability sampling through households may not produce sufficient cases of diseases that are not highly prevalent. In such cases, an attractive alternative design is multistage probability sampling through sites of care, in which all persons in the reference population have some chance of random selection through their medical providers, and in which included subjects are selected with known probability. DATA COLLECTION AND PRINCIPAL
FINDINGS: Multistage national probability sampling through providers supplies uniquely valuable information, but will not represent populations not receiving medical care and may not provide sufficient cases in subpopulations of interest. Factors contributing to the substantial cost of such a design include the need to develop a sampling frame, the problems associated with recruitment of providers and subjects through medical providers, the need for buy-in from persons affected by the disease and their medical practitioners, as well as the need for a high participation rate. Broad representation from the national community of scholars with relevant expertise is desirable. Special problems are associated with organization of the research effort, with instrument development, and with data analysis and dissemination in such a consortium.
CONCLUSIONS: Multistage probability sampling through providers can provide unbiased, nationally representative data on persons receiving regular medical care for uncommon diseases and can improve our ability to accurately study care and its outcomes for diseases such as HIV/AIDS. However, substantial costs and special circumstances are associated with the implementation of such efforts.

Entities:  

Mesh:

Year:  1999        PMID: 10591267      PMCID: PMC1089067     

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  14 in total

1.  National probability samples in studies of low-prevalence diseases. Part II: Designing and implementing the HIV cost and services utilization study sample.

Authors:  M R Frankel; M F Shapiro; N Duan; S C Morton; S H Berry; J A Brown; M A Burnam; S E Cohn; D P Goldman; D F McCaffrey; S M Smith; P A St Clair; J F Tebow; S A Bozzette
Journal:  Health Serv Res       Date:  1999-12       Impact factor: 3.402

2.  The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium.

Authors:  S A Bozzette; S H Berry; N Duan; M R Frankel; A A Leibowitz; D Lefkowitz; C A Emmons; J W Senterfitt; M L Berk; S C Morton; M F Shapiro
Journal:  N Engl J Med       Date:  1998-12-24       Impact factor: 91.245

3.  Fee-for-data: a strategy to open the HMO black box.

Authors:  W P Welch; H G Welch
Journal:  Health Aff (Millwood)       Date:  1995       Impact factor: 6.301

4.  Physician and plan effects on satisfaction of Medicaid managed care patients with their health care and providers.

Authors:  D M Harris; P Hanes; H Jimison; D Jones; J Bryan-Wilson; M R Greenlick
Journal:  J Ambul Care Manage       Date:  1997-01

5.  Measuring quality of life in a reformed health system.

Authors:  A F Lehman
Journal:  Health Aff (Millwood)       Date:  1995       Impact factor: 6.301

6.  Revisiting the behavioral model and access to medical care: does it matter?

Authors:  R M Andersen
Journal:  J Health Soc Behav       Date:  1995-03

7.  Meeting the service needs of HIV-infected persons: is the Ryan White CARE Act succeeding?

Authors:  R Marx; M H Katz; M S Park; R J Gurley
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-01-01

8.  Differences in 4-year health outcomes for elderly and poor, chronically ill patients treated in HMO and fee-for-service systems. Results from the Medical Outcomes Study.

Authors:  J E Ware; M S Bayliss; W H Rogers; M Kosinski; A R Tarlov
Journal:  JAMA       Date:  1996-10-02       Impact factor: 56.272

9.  AIDS treatment costs during the last months of life: evidence from the ACSUS.

Authors:  F J Hellinger; J A Fleishman; D C Hsia
Journal:  Health Serv Res       Date:  1994-12       Impact factor: 3.402

Review 10.  Stigma, HIV and AIDS: an exploration and elaboration of a stigma trajectory.

Authors:  A A Alonzo; N R Reynolds
Journal:  Soc Sci Med       Date:  1995-08       Impact factor: 4.634

View more
  34 in total

1.  Sex differences in pain and misuse of prescription analgesics among persons with HIV.

Authors:  Jennie C I Tsao; Judith A Stein; Aram Dobalian
Journal:  Pain Med       Date:  2010-04-29       Impact factor: 3.750

2.  Use of alternative therapists among people in care for HIV in the United States.

Authors:  Andrew S London; Carrie E Foote-Ardah; John A Fleishman; Martin F Shapiro
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

3.  Circumstances at HIV diagnosis and progression of disease in older HIV-infected Americans.

Authors:  D S Zingmond; N S Wenger; S Crystal; G F Joyce; H Liu; U Sambamoorthi; L A Lillard; A A Leibowitz; M F Shapiro; S A Bozzette
Journal:  Am J Public Health       Date:  2001-07       Impact factor: 9.308

4.  National probability samples in studies of low-prevalence diseases. Part II: Designing and implementing the HIV cost and services utilization study sample.

Authors:  M R Frankel; M F Shapiro; N Duan; S C Morton; S H Berry; J A Brown; M A Burnam; S E Cohn; D P Goldman; D F McCaffrey; S M Smith; P A St Clair; J F Tebow; S A Bozzette
Journal:  Health Serv Res       Date:  1999-12       Impact factor: 3.402

5.  Effects of HIV Medication Complexity and Depression on Adherence to HIV Medication.

Authors:  Virender Kumar; William Encinosa
Journal:  Patient       Date:  2010-03-01       Impact factor: 3.883

6.  A two-stage sampling method for clinical surveillance of individuals in care for HIV infection in the United States.

Authors:  Patrick S Sullivan; John M Karon; Faye E Malitz; Stephanie Broyles; Eve D Mokotoff; Susan E Buskin; Patricia L Fleming
Journal:  Public Health Rep       Date:  2005 May-Jun       Impact factor: 2.792

7.  Progress toward implementation of integrated systems for surveillance of HIV infection and morbidity in the United States.

Authors:  Patrick S Sullivan; Matthew T McKenna; Robert S Janssen
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

8.  Scope of rapid HIV testing in private nonprofit urban community health settings in the United States.

Authors:  Laura M Bogart; Devery Howerton; James Lange; Kirsten Becker; Claude Messan Setodji; Steven M Asch
Journal:  Am J Public Health       Date:  2008-02-28       Impact factor: 9.308

9.  The relationship between type of mental health provider and met and unmet mental health needs in a nationally representative sample of HIV-positive patients.

Authors:  Stephanie L Taylor; M Audrey Burnam; Cathy Sherbourne; Ron Andersen; William E Cunningham
Journal:  J Behav Health Serv Res       Date:  2004 Apr-Jun       Impact factor: 1.505

10.  Scope of rapid HIV testing in urban U.S. hospitals.

Authors:  Laura M Bogart; Devery Howerton; James Lange; Kirsten Becker; Claude Messan Setodji; Steven M Asch
Journal:  Public Health Rep       Date:  2008 Jul-Aug       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.